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Abstract
Lenalidomide is an integral, yet evolving, part of current treatment pathways for both transplant-eligible and transplant-ineligible
patients with newly diagnosed multiple myeloma (NDMM). It is approved in combination with dexamethasone as first-line
therapy for transplant-ineligible patients with NDMM, and as maintenance treatment following autologous stem cell transplan-
tation (ASCT). Although strong clinical trial evidence has supported the integration of lenalidomide into current treatment
paradigms for NDMM, applying those paradigms to individual patients and determining which patients are most likely to benefit
from lenalidomide treatment are more complex. In this paper, we utilize the available clinical trial evidence to provide recom-
mendations for patient selection and lenalidomide dosing in both the first-line setting in patients ineligible for ASCT and the
maintenance setting in patients who have undergone ASCT. In addition, we provide guidance on management of those adverse
events that are most commonly associated with lenalidomide treatment, and consider the optimal selection and sequencing of
next-line agents following long-term frontline or maintenance treatment with lenalidomide.
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Introduction
The treatment of multiple myeloma (MM), a cancer charac-
terized by the clonal expansion of plasma cells [1, 2], has
progressed rapidly in recent years. Numerous agents for the
treatment of newly diagnosed MM (NDMM) are now avail-
able or in development, providing clinicians with a wide array
of therapeutic options [3–5]. Whether autologous stem cell
transplantation (ASCT) should be used as a first-line strategy
in a given subject is a vital clinical decision that must be made
soon after diagnosis, and it determines which of two distinct
treatment pathways patients will follow [6, 7]. In addition to
prolonged progression-free survival (PFS) [8–10], studies
have previously shown that patients who undergo ASCT are
more likely to achieve a complete response (CR) and minimal
residual disease (MRD)-negative status [11] than those who
do not, even in the era of novel agents [12, 13]. Although
results from the recent FORTE trial showed little difference
in response and MRD negativity rates in newly diagnosed
patients who do not, versus those who do, undergo transplan-
tation [14], ASCT remains the current first-line standard of
care for patients who are able to tolerate this more intensive
form of therapy [15]. While stem cells may be collected dur-
ing first-line treatment and reserved for subsequent ASCT
[16], most patients who are eligible for ASCT undergo induc-
tion therapy—usually incorporating at least one novel anti-
myeloma agent—followed immediately by high-dose therapy
and ASCT. Patients may subsequently receive consolidation
and/or maintenance therapy. Individuals who are ineligible for
ASCTowing to either advanced age or comorbidities follow a
different therapeutic path, generally receiving prolonged first-
line treatment with a combination of two or more anti-
myeloma agents [17, 18].
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While most patients ultimately receive multiple lines of
therapy during the course of their disease, many do not survive
beyond first-line treatment [12]; a deep and durable response
to first-line therapy is thus a particularly important treatment
goal [19]. The continued development, approval, and valida-
tion of increasingly effective combinations of new anti-
myeloma agents have increased the likelihood of patients
achieving this goal, regardless of the treatment pathway
adopted.
The immunomodulatory drug lenalidomide is an integral
part of current treatment pathways for both transplant-
ineligible and transplant-eligible patients. In newly diagnosed
patients not planned to undergo ASCT, lenalidomide plus
dexamethasone is approved as a first-line regimen in the
United States (US) [20]; in Europe, lenalidomide is indicated
for first-line use in combination with dexamethasone with or
without bortezomib, and also with melphalan plus prednisone
[21]. For patients who do undergo ASCT, single-agent
lenalidomide is approved as maintenance treatment post-
transplantation [20, 21]; in the US, this applies to any line of
treatment [20], whereas the European indication specifies
maintenance following first-line ASCT only [21].
This review provides an overview of key studies
supporting the approval of lenalidomide in the frontline and
maintenance settings. It also presents clinical recommenda-
tions for the use of lenalidomide as a component of frontline
regimens for patients who are ineligible for ASCT, and as
maintenance therapy for patients who have undergone front-
line ASCT.
Key clinical trials of lenalidomide in NDMM
Lenalidomide as first-line therapy in patients
ineligible for, or not scheduled for immediate,
transplantation
The approval and use of lenalidomide as a first-line treatment
for NDMM patients not undergoing ASCT are supported by
two large phase 3 clinical trials, the Frontline Investigation of
Revlimid and dexamethasone versus Standard Thalidomide
(FIRST) and MM-015 trials, which included patients aged ≥
65 years or ineligible for ASCT because of comorbidities
(Table 1) [22, 23]. In FIRST, lenalidomide plus low-dose
dexamethasone (Rd) taken continuously until disease progres-
sion significantly prolonged PFS versus either 12 cycles of
melphalan, prednisone, and thalidomide (MPT) or eighteen
28-day cycles of Rd (Rd18) [22, 24]. It should be noted, how-
ever, that the median duration of actual treatment differed little
between the continuous Rd and Rd18 arms in FIRST:
18.4 months and 16.6 months, respectively [22]. Median
PFS with Rd until progression was 26 months in FIRST
[24], compared with a median PFS of 30 months in patients
who received six cycles of Rd in the Southwest Oncology
Group (SWOG) S0777 trial [16], and 32 months in patients
who received Rd for a median of 21.3 months in MAIA [25].
Continuous Rd also significantly increased overall survival
(OS) versus MPT, but not versus Rd18, in FIRST (OS was
similar in the continuous Rd and Rd18 groups) [24]. In MM-
015, first-line melphalan, prednisone, and lenalidomide
(MPR) followed by continuous lenalidomide until progression
(MPR-R) significantly prolonged PFS versus either MPR or
melphalan plus prednisone (MP) without subsequent
lenalidomide (Table 1) [23]. The subsequent phase 3 EMN
01 trial, which compared MPR versus cyclophosphamide,
prednisone, and lenalidomide (CPR) versus Rd, reported sim-
ilar efficacy for MPR versus Rd (Table 1) but a clearly more
favorable adverse event (AE) profile for Rd [26], despite mel-
phalan being dose-reduced when compared with the “classic”
MP schedule. In the first prospective, randomized, phase 3
trial to apply a frailty-adjusted approach to the treatment of
elderly patients with NDMM and an intermediate level of
fitness, patients with an International Myeloma Working
Group (IMWG) frailty score of 1 were randomized to receive
either continuous standard-dose Rd or dose/schedule-adjusted
Rd induction followed by lenalidomide maintenance [27]
(Table 1). After 25 months’ median follow-up, similar re-
sponses, PFS, and OS were observed in the two treatment
arms.
Recent phase 3 trials have shown that the beneficial effects
of Rd in the treatment of NDMM can be enhanced by combi-
nation with a second novel agent. In the SWOG S0777 phase
3 trial, adding the proteasome inhibitor bortezomib (V) to the
Rd doublet backbone (VRd) further prolonged both PFS and
OS versus Rd alone as induction therapy in newly diagnosed
patients not proceeding to immediate ASCT (Table 1) [16].
Consequently, the VRd triplet is now approved in Europe for
use solely in patients deemed ineligible for ASCT [21]. In the
phase 3 MAIA trial, the monoclonal antibody daratumumab
(D) was added to Rd (DRd), significantly prolonging PFS and
increasing MRD negativity and ≥CR rates versus Rd alone
(Table 1) [25]. DRd is now also approved in Europe for the
treatment of patients with NDMM who are ineligible for
ASCT [28].
Lenalidomide as maintenance therapy following
transplantation
Numerous clinical studies have demonstrated the benefits of
post-ASCT lenalidomide maintenance treatment in patients
with NDMM [10, 29–32]; indeed, two of these studies—
Cancer and Leukemia Group B (CALGB) 100104 and
Intergroupe Francophone du Myélome (IFM)-2005-02—
formed the basis for the approval of lenalidomide in this indi-
cation (Table 2) [29, 30]. Both of these studies randomized
newly diagnosed patients in remission after ASCT to
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continuous treatment with lenalidomide or placebo until dis-
ease progression [29, 30, 32]. Although 67% of patients in the
CALGB 100104 placebo group who did not have progressive
disease at this point crossed over to lenalidomide after a medi-
an of 18 months’ follow-up, median time to progression (TTP)
and OS were significantly longer in the lenalidomide group
[30]. Similarly, lenalidomide maintenance significantly in-
creased median PFS versus placebo in IFM-2005-02, although
no significant improvement in OS was observed [29]. In order
to clarify the effect of lenalidomide treatment on survival out-
comes, a meta-analysis was conducted of outcomes in patients
who received post-ASCTmaintenance in the CALGB 100104,
IFM-2005-02, and Gruppo Italiano Malatti Ematologiche
dell’Adulto (GIMEMA) RV-MM-PI-209 trials (Table 2) [33].
Of note, patients in the latter were considered on an intent-to-
treat basis from the start of first-line therapy. The meta-analysis
confirmed a beneficial effect of lenalidomide maintenance on
both PFS and OS, despite this not being consistently evident in
the individual studies. In addition, both the meta-analysis and
the Myeloma XI study showed an improvement in PFS after
next therapy (PFS2), indicating that lenalidomide maintenance
does not induce progressive disease that is resistant to second-
line therapy [31, 33].
A recent Belgian study investigated the impact of
lenalidomide maintenance on several T cell subsets and
myeloid-derived suppressor cells in blood samples from 17
patients with MM who had undergone ASCT [34].
Lenalidomide maintenance was found to increase the propor-
tion of naïve CD8+ and several memory T cell types, while
reducing numbers of CD4 and CD8+ terminal effector T cells.
The immunosuppressive potential of regulatory T cells be-
came more pronounced with lenalidomide treatment, whereas
the activity of myeloid-derived suppressor cells was reduced.
The authors concluded that the frequently reported beneficial
effects of post-ASCT lenalidomide maintenance on survival
outcomes in patients with MM most likely result from a net
immunostimulatory effect against residual MM cells.
Lenalidomide as first-line therapy in NDMM
patients ineligible for ASCT: patient selection
and dosing
Patient selection
While lenalidomide is indicated in combination with dexa-
methasone for the treatment of patients with MM in the US
[20], the European label is more specific. For patients with
NDMM who are ineligible for ASCT, this approves
lenalidomide in combination with the following: dexametha-
sone until disease progression or unacceptable toxicity;
bortezomib and dexamethasone for a maximum of eight 21-
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combination with only dexamethasone; or MP for up to nine
28-day cycles followed by lenalidomide monotherapy [21].
As MM is a highly heterogeneous disease and patient re-
sponses to any treatment can vary widely, it is important to
determine whether a lenalidomide-based regimen is the best
therapeutic option for each individual patient, and to consider
how patient- and disease-specific characteristics might impact
on the efficacy and feasibility of lenalidomide treatment.
Fortunately, results from the pivotal clinical trials described
earlier provide some insight into these issues. Real-world data
and the results from other clinical trials should also be taken
into consideration during clinical decision-making, along with
international guidelines and recommendations such as those
issued by the US National Comprehensive Cancer Network
(NCCN) [15], the European Society for Medical Oncology
(ESMO) [35], the IMWG [36], and the European Myeloma
Network [37]. Although approved in Europe, MPR-R is not
recommended by the NCCN or ESMO for the treatment of
transplant-ineligible patients; therefore, this review focuses
principally on the more widely used and recommended Rd.
Bone marrow function is an important consideration when
selecting the initial treatment regimen for ASCT-ineligible pa-
tients. According to the European label, absolute neutrophil
count (ANC) must be ≥ 1.0 × 109/L and/or platelet count ≥
50 × 109/L prior to commencing treatment with Rd [21]. Renal
impairment must also be considered prior to starting treatment.
As lenalidomide is excreted renally, patients with impaired renal
function may require dose adjustments (see below) that could
impact on treatment efficacy; thus, depending on the severity of
renal impairment and the level of dose adjustment required,
alternative regimens may be more appropriate options. In the
FIRST trial, patients with mild-to-moderate renal impairment
(creatinine clearance [CrCl] ≥ 30 to < 80 mL/min) who received
continuous Rd obtained a similar PFS benefit versus MPT to
those with normal renal function, despite dose adjustments;
these benefits were coupled with improved renal function in
the majority of patients with IMWG-defined complete renal
response (CRrenal; this was achieved by 23.8% and 14.3% of
Rd and MPT recipients, respectively) [38]. The observed im-
provement in renal function may have resulted from elimination
of the toxic free light chains that are associated with MM.
However, no benefit of Rd over MPTwas noted in patients with
severe renal impairment (CrCl < 30 mL/min), suggesting that
Rd may not be the optimal treatment choice for this patient
population. Based on IMWG recommendations, bortezomib-
based regimens should be considered for such patients [39].
Sub-analyses of the pivotal clinical trial data in patients
ineligible for ASCTsuggest that the survival benefit seen with
lenalidomide-based regimens versus comparators is largely
independent of many patient- and disease-related factors, in-
cluding gender, ethnicity, International Staging System (ISS)
stage, renal function, Eastern Cooperative Oncology Group
(ECOG) performance status, and β2-microglobulin level [22,
40]. In the FIRST trial, continuous Rd was more effective in
prolonging survival than MPT, regardless of whether patients
were older or younger than 75 years [22, 40]. However, long-
term data from this trial suggested that continuous Rd offered
no survival benefit versus MPT in patients with high-risk cy-
togenetics or high lactate dehydrogenase (LDH) levels at di-
agnosis [24]. These latter findings are in contrast to those from
the SWOG S0777 trial, which reported a greater beneficial
effect of VRd versus Rd in patients with high-risk cytogenet-
ics than in the overall population [16]. A pooled analysis of
data from the GIMEMA MM-03-05 and EMN 01 trials also
found that, in patients with high-risk cytogenetics, treatment
with a bortezomib-based regimen significantly prolonged
both PFS and OS versus lenalidomide-based treatment [41].
These data suggest that adding a proteasome inhibitor to Rd
may help overcome the adverse prognostic impact of high-risk
cytogenetics, and is consistent with the IMWG recommenda-
tion that NDMM patients with high-risk cytogenetics receive
combination therapy with a proteasome inhibitor,
lenalidomide or pomalidomide, and dexamethasone [42].
When selecting a first-line therapy for NDMM patients
ineligible for ASCT, physicians should carry out a full work-
up, including tests for cytogenetics, renal function, hemato-
logic function, and venous thromboembolism risk, to enable
them to assess the suitability of a lenalidomide-based regimen,
and whether Rd is the most appropriate treatment or whether
bortezomib should be added. Guidance on managing the tox-
icities most commonly encountered with lenalidomide-based
regimens is provided later in this review.
Dosing and treatment duration
When used in combination with dexamethasone, lenalidomide
is administered at a dosage of 25 mg once daily on days 1–21
of 28-day cycles [20, 21]. Dexamethasone dosing is normally
40mg once daily on days 1, 8, 15, and 22 of each 28-day cycle,
although the starting dose may be reduced to 20 mg once daily
in patients aged > 75 years [20, 21]. Dexamethasone dose re-
duction was successfully demonstrated in the previously de-
scribed trial investigating a frailty-adjusted approach in elderly
patients with intermediate levels of fitness [27]. In that trial,
treatment with 9 cycles of lenalidomide in combination with
dexamethasone 20 mg once weekly, followed by lenalidomide
maintenance until progression, was associated with response
rates and survival outcomes that were comparable with those
seen with continuous standard-dose Rd. Rates of non-
hematologic grade 3/4 AEs, and lenalidomide dose reductions
and discontinuations, were reduced with the modified Rd-R
regimen versus continuous standard-dose Rd, and the
lenalidomide median relative dose intensity was 100% versus
90%. On the basis of these findings, pre-emptive dexametha-
sone dose reductions should be considered in frail and/or el-
derly patients as a means of reducing the risk of toxicities that
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could negatively impact treatment adherence and outcomes in
such populations. The starting dose of lenalidomide may also
be reduced in elderly patients; however, this is not in accor-
dance with the approved use, and studies to confirm compara-
ble efficacy are needed. Administration of both lenalidomide
and dexamethasone should be continued until either disease
progression or intolerance [20, 21].
When combined with bortezomib and dexamethasone, the
lenalidomide dosage is 25 mg once daily on days 1–14 of 21-
day cycles, with bortezomib administered subcutaneously at a
dosage of 1.3 mg/m2 on days 1, 4, 8, and 11 of each cycle (a
recent review and meta-analysis confirmed similar survival
and response rates with subcutaneous [sc] versus intravenous
bortezomib, but significantly reduced rates of adverse events
such as peripheral sensory neuropathy, fatigue, and thrombo-
cytopenia [43]. As bortezomib was administered intravenous-
ly in SWOG-0777 [15], switching to sc administration would
be expected to lead to noticeably lower bortezomib-associated
neurologic toxicity rates than were reported in that trial). This
regimen is recommended for a maximum of eight cycles be-
fore bortezomib is omitted and treatment continued with
lenalidomide (25 mg once daily on days 1–21) plus dexameth-
asone in 28-day cycles until either disease progression or un-
acceptable toxicity [21].
Lenalidomide dose adjustments are required for patients
with renal impairment, regardless of which regimen is used.
The recommended dose in patients with moderate renal im-
pairment is 10mg once daily; if the patient is able to tolerate it,
this may be increased to 15mg if he or she does not respond to
treatment with 10 mg once daily [20, 21]. Patients with severe
renal impairment not requiring dialysis should receive 15 mg
every second day or 7.5 mg daily if this latter capsule size is
available locally. Individuals with severe renal impairment
requiring dialysis should receive 5 mg once daily; on dialysis
days, lenalidomide should be administered after dialysis.
It is important for patients to remain on lenalidomide treat-
ment for as long as possible; this is underscored by the FIRST
study, in which both PFS and time to next treatment (TTNT)
were prolonged in patients receiving continuous Rd versus
those assigned toRd18 (median PFS, 26.0 versus 21.0months,
respectively; median TTNT, 36.7 versus 28.5 months) [22,
24]. Dosing should be adjusted for toxicity, and any problems
addressed as quickly and effectively as possible in order to
enable patients to continue with the prescribed regimen and
achieve the maximal benefit.
Use of lenalidomide as maintenance therapy
Patient selection
In both the US and Europe, lenalidomide is recommended as
maintenance therapy following ASCT in patients with
NDMM [15, 35]. As with first-line use in patients ineligible
for ASCT, it is important to consider an individual patient’s
likelihood of benefiting from maintenance therapy before
making treatment recommendations. Single-agent
lenalidomide maintenance, like Rd, can be given until pro-
gression; thus, patients at increased risk of potential compli-
cations owing to long-term lenalidomide exposure should be
identified in advance (this will be discussed later in the toxic-
ity section). In addition to the clinical trial data described
earlier, findings from real-world studies [44–46] and addition-
al clinical trials [31] may be valuable in this respect. Although
the pivotal studies suggest that many patients will benefit from
maintenance treatment with lenalidomide, these results must
be interpreted with caution. The findings from the pivotal
studies and the associated meta-analysis show an overall ben-
efit of lenalidomide maintenance, albeit with some heteroge-
neity between individual studies and subgroups; thus, individ-
ual treatment decisions should be made on a case-by-case
basis.
In view of the known hematologic toxicity of lenalidomide,
patients with compromised bone marrow function following
ASCT may not be suitable for maintenance therapy and/or
may require a delay in treatment until their hematologic func-
tion has recovered to an adequate level. According to both the
US prescribing information and the European summary of
product characteristics, lenalidomide maintenance post-
ASCT should only be initiated when ANC is ≥ 1.0 × 109/L
and/or platelet count ≥ 75 × 109/L [20, 21]. Additionally,
lenalidomide should not be administered to patients with a
history of severe rash associated with thalidomide treatment
[20, 21].
It is not yet clear whether patients can be selected for
lenalidomide maintenance on the basis of individual patient-
and disease-specific characteristics. A number of studies have
analyzed the impact of disease stage on survival, with no clear
consensus [10, 31, 33]. The largest of these was the meta-
analysis discussed above, which suggested that patients with
ISS stage I or II disease may derive more benefit from
lenalidomide maintenance than those with stage III disease
[33]. Individual studies suggest that lenalidomide mainte-
nance may be equally advantageous for patients of all ages
[10, 29, 31], although the results of the meta-analysis indicat-
ed a reduced survival benefit in patients aged > 60 years [33].
While relevant data were not available for all patients, the
same analysis found that lenalidomide maintenance provided
no OS benefit in patients with elevated LDH levels or CrCl <
50 mL/min at diagnosis [33], suggesting that its value may be
limited in such populations. Similarly, the benefits and risks of
lenalidomide in patients with impaired hepatic function
should be carefully evaluated, as these patients may be at risk
of potentially fatal hepatotoxicity [20].
As is the case for definitive first-line therapy, the relative
benefit of lenalidomide maintenance versus no maintenance is
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limited in patients with high-risk cytogenetics, but is typically
much greater in patients with standard-risk cytogenetics [10,
33]. Nevertheless, some studies suggest that lenalidomide
maintenance significantly prolongs survival and/or TTNT ver-
sus no maintenance in patients considered at high cytogenetic
risk [31, 46]. In the Myeloma XI trial, lenalidomide mainte-
nance prolonged both PFS and OS versus observation in all
cytogenetic risk groups (standard, high, and ultra-high) [31].
Three-year OS with lenalidomide maintenance versus obser-
vation was 74.9% versus 63.7% among high-risk patients, and
62.9% versus 43.5% among those considered to be at ultra-
high risk. However, as these subgroup analyses were not ad-
equately powered for direct comparison, the authors advise
that their findings are inconclusive and must be interpreted
with caution.
As well as varying with cytogenetic risk profile, the bene-
fits of lenalidomide maintenance may differ according to the
depth of response to ASCT, with patients who achieve deeper
responses (≥ very good partial response [VGPR]) appearing to
derive greater benefit than those with a lesser response [33].
Taken together, these findings suggest that alternatives to
lenalidomide maintenance (for example, bortezomib adminis-
tered for 2 years [47]), or even nomaintenance treatment, may
be preferable in patients with high-risk cytogenetics or with a
lesser response to ASCT. All other patients may benefit from
lenalidomide maintenance, and suitability should be assessed
on a case-by-case basis.
Dosing
When given as maintenance treatment, the recommended
starting dose of lenalidomide is 10 mg once daily on days
1–28 of repeated 28-day cycles, until either disease progres-
sion or unacceptable toxicity [20, 21]. If tolerated, the dose
may be increased to 15 mg/day after three cycles of
lenalidomide maintenance [20, 21], consistent with the dosing
regimen used in pivotal clinical trials [29, 30]. In routine clin-
ical practice, prolonged treatment at these dosages may be
achievable in only a proportion of patients; however, real-
world data suggest that dose reductions do not adversely im-
pact PFS [48]. The US prescribing information recommends
that patients with moderate renal impairment (CrCl 30–
60 mL/min) receive 5 mg once daily, while those with severe
renal impairment (CrCl < 30 mL/min), regardless of whether
dialysis is required, receive 2.5 mg once daily. In Europe, the
recommendation is 10 mg once daily in patients with 30 ≤
CrCl < 50 mL/min, 7.5 mg once daily or 15 mg every second
day in patients with severe renal impairment not requiring
dialysis, and 5 mg once daily in patients with end-stage renal
disease requiring dialysis [20]. In patients undergoing dialysis,
lenalidomide should always be administered after dialysis [20,
21].
Determining the optimal duration of lenalidomide
maintenance treatment
In most studies, including the pivotal phase 3 trials, it was
intended that lenalidomide should be administered until the
development of either disease progression or unacceptable
toxicity [10, 29–31, 33]; in practice, however, the actual du-
ration of maintenance treatment has varied. In the IFM 2005-
02 trial, the median duration of lenalidomide maintenance
administration was approximately 2 years, while in the
CALGB 100104 and GIMEMA RV-MM-PI-209 trials, it
was 2.5 and 3 years, respectively [33]. Whether fixed-
duration maintenance results in improved outcomes versus
treatment until progression is currently unclear. A retrospec-
tive analysis of 464 patients who received lenalidomide main-
tenance post-ASCT suggested an association between longer
duration of maintenance therapy and improved PFS and OS;
however, this particular analysis was limited by its retrospec-
tive nature, in addition to missing data and a lack of standard-
ization for second primary malignancy (SPM) screening [49].
In the phase 3 GMMG-MM5 study, patients received one of
two bortezomib-based induction regimens followed byASCT,
as well as lenalidomide consolidation and maintenance for
either 2 years or until the achievement of CR [50]. OS was
significantly longer in 2-year lenalidomide recipients than in
those who received maintenance only until CR (hazard ratio
[HR] 1.42 [95% CI, 1.04–1.93]; p = 0.03). Interestingly, only
35% of patients assigned to 2 years of maintenance actually
received treatment for this length of time; even fewer patients
in the treatment until CR arms (14–18%) received 2 full years
of treatment. Whether continued maintenance can achieve
further cytoreduction and potentially even eliminate residual
myeloma cells remains to be seen. Thus, based on the avail-
able data, lenalidomide maintenance should be given for as
long as possible.
Management of hematologic AEs
Neutropenia
Neutropenia is the most common and most significant
lenalidomide-associated AE, and occurs most frequently at
grade 3 or 4 (Tables 3 and 4). Grade 3/4 neutropenia was
reported in 30% of patients receiving first-line continuous
Rd in the FIRST trial [24], and high rates have been reported
with long-term maintenance also: 51% and 50% in
lenalidomide-treated patients in IFM-2005-02 and CALGB
100104, respectively [29, 30]. Like most hematologic AEs
seen with lenalidomide, neutropenia occurs most frequently
during the first 6 months of treatment, with incidences declin-
ing over time [22], and can be managed by interrupting treat-
ment, monitoring complete blood count, and waiting until
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toxicities resolve before starting the next treatment cycle [51].
Physicians should carry out a complete blood cell count—
including white blood cell count with differential count, plate-
let count, hemoglobin, and hematocrit—at baseline, weekly
for the first 8 weeks, and thenmonthly thereafter [21]. Patients
with neutropenia should be monitored for signs of infection
[52]. If hematologic toxicity continues, stepwise reductions of
the lenalidomide dose should be implemented according to the
prescribing information or summary of product characteris-
tics, and growth factor support should be considered if neu-
tropenia is severe and/or the only toxicity observed [20]. In
patients receiving first-line treatment, lenalidomide may be re-
introduced at the next higher dose level, up to the starting
dose, upon improvement of bone marrow function, as indicat-
ed by a lack of hematologic toxicity for at least two consecu-
tive cycles (i.e., ANC ≥ 1.5 × 109/L with platelet count ≥
100 × 109/L at the beginning of a new cycle) [21]. Patients
should be advised to promptly report febrile episodes. Rates
of grade 3/4 febrile neutropenia in the FIRST trial were 1%
with continuous Rd and 3% with Rd18 [24], while rates of up
to 17% have been reported in maintenance studies [20].
Thrombocytopenia
Grade 3/4 thrombocytopenia was reported in 9% of patients
receiving first-line continuous Rd in FIRST [24], while the
incidence of such events in patients receiving post-ASCT
lenalidomide maintenance in the IFM-2005-02 and CALGB
100104 studies was 14% and 15%, respectively (Tables 3 and
4) [29, 30]. Patients and physicians should watch for signs and
symptoms of bleeding, including petechiae and epistaxes, es-
pecially in patients treated concomitantly with medicines that
may induce bleeding [21]. Complete blood counts should be
taken weekly, particularly during the first few cycles, and the
dose interrupted if platelet levels fall to < 30,000/mm3 [52].
Once platelet levels have recovered, treatment should be re-
sumed at the next lower dose. For each subsequent drop to <
30,000/mm3, treatment should be interrupted and resumed at
the next lowest dose upon recovery. Platelet transfusions ac-
cording to standard clinical practice may be necessary. There
are currently no recommendations supporting the use of
thrombopoietic agents to manage thrombocytopenia in pa-
tients receiving lenalidomide treatment.
Anemia
Anemia is most common among patients treated with first-line
lenalidomide-containing regimens, with grade 3 or 4 events
affecting 19% of those treated with continuous Rd in FIRST
[24]. By contrast, the incidence of grade 3/4 anemia was 3–5%
in patients receiving lenalidomide maintenance in IFM-2005-
02 and CALGB 100104 (Table 4) [29, 30]. As for thrombo-
cytopenia, the incidence of anemia appears relatively consis-
tent over time, occurring only slightly more frequently during
the first 6 months of treatment [22]. Although erythropoiesis-
stimulating agents (ESAs) are recommended for MM patients
Table 4 Incidence of selected grade ≥ 3adverse events and second primary malignancies in key clinical trials of lenalidomide maintenance therapy
post-autologous stem cell transplantation
CALGB 100104 [30]
Median follow-up: 91 months
IFM-2005-02 [29]
Median follow-up: 45 months
Myeloma XI [31]





Lenalidomide Placebo Lenalidomidea Observation
n = 231 n = 143 n = 86 n = 306 n = 302 n = 1137 n = 834
Neutropenia 35/15 5/3 30/5 51 18 28/5 NR
Anemia 4/1 0/0 1/0 3 2 4/1 NR
Thrombocytopenia 10/5 0/5 3/2 14 7 4/2 NR
Fatigue/lethargy 0/0 0/0 0/0 5 2 1/0 NR
Diarrhea 5/0 1/0 3/0 2 < 1 NR NR
Constipation NR NR NR 1 0 < 1/0 NR
Infection 6/1 2/0 5/0 13 5 11/1 NR
Cardiac disorder NR NR NR NR NR 0/0 NR
Rash 4/0 1/0 1/0 3 2 1/< 1 NR
Thromboembolic event NR NR NR 2/1c 1/0c NR NR
Second primary malignancyd, % 19 3 15 10 4 5/3e NR
aGrade 3/4. b Patients who crossed over to lenalidomide treatment during the trial. c Deep-vein thrombosis/pulmonary embolism. d Not graded. e 3-year
cumulative incidence
NR, not reported
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with persistent symptomatic anemia [53], these agents should
be used with caution, as they may increase the risk of throm-
boembolism when co-administered with lenalidomide and
dexamethasone [54]. Otherwise, anemia should be managed
according to standard clinical practice, and severe cases may
require transfusions.
Thromboembolism
Thromboembolism is a serious lenalidomide-associated AE
that occurs most frequently during first-line treatment, as the
risk is elevated when co-administered with dexamethasone
(Tables 3 and 4) [22 , 23 , 29 , 32 , 55] . Despi te
thromboprophylaxis with either low-dose aspirin or a low-
molecular-weight heparin, heparin, or warfarin, 5% of patients
treated with continuous Rd in the FIRST trial experienced
deep-vein thrombosis (DVT), and 4% developed a pulmonary
embolism (PE) [24]. When given as maintenance therapy fol-
lowing ASCT, thromboembolic events rarely occur with
lenalidomide treatment if co-administered with judicious
anticoagulation [29, 32]. No patients were affected in the
CALGB 100104 trial, in which all those considered to be at
high risk of DVT or PE received aspirin, warfarin, or heparin
[32]; however, in the IFM-2005-02 trial, in which
thromboprophylaxis was not used, 6% of lenalidomide-
treated patients developed any-grade DVT or PE [29].
Although thromboembolism may occur at any time, it usually
occurs more frequently in the first months of lenalidomide
therapy; hence, physicians should monitor patients particular-
ly closely during the early stages of therapy [22, 55, 56].
Prophylactic antithrombotic medications should be recom-
mended to all patients taking lenalidomide, especially those
with additional thrombotic risk factors [21, 57]. Based on
clinical trial data in patients receiving first-line lenalidomide-
based regimens, oral anticoagulation with low-dose aspirin
may be an effective and less expensive alternative to low-
molecular-weight heparin (LMWH) prophylaxis in patients
with low thromboembolic risk [56]. Recently published data
for apixaban, a new direct factor Xa inhibitor, suggest that
agents of this type may also constitute a safe and convenient
thromboprophylactic alternative to LMWHs in this indication
[58]. Aspirin or a LMWH should, unless contraindicated, be
administered to patients receiving epoietin therapy concomi-
tantly with lenalidomide maintenance [32], and patients with
known risk factors for thromboembolism, including prior
thrombosis, should be closely monitored and all modifiable
risk factors minimized [21].Medications that may increase the
risk of thrombosis, such as hormone replacement therapy,
should be used with caution in patients receiving Rd [20].
Patients and physicians should be alert to the signs of throm-
boembolism, including shortness of breath, chest pain, or arm
or leg edema [20, 21]. If any thromboembolic events occur,
treatment should be discontinued and anticoagulation therapy
commenced; lenalidomide treatment may be restarted, along
with appropriate antithrombotic therapy, once the thromboem-
bolic event has been treated, and after a careful risk-benefit
assessment [21].
Management of non-hematologic AEs
Physicians should be alert for non-hematologic AEs and man-
age any that arise as promptly and effectively as possible, in
order to facilitate optimal dosing, minimize treatment disrup-
tions and discomfort to patients, and maximize treatment du-
ration and benefit [52, 59]. Patients and caregivers should be
informed of the potential for adverse reactions and their pos-
sible symptoms and manifestations, and be encouraged to re-
port any early signs. Peripheral neuropathy, which can be
problematic with other novel agents such as bortezomib and
thalidomide [60–62], is fortunately seen far less frequently in
patients treated with lenalidomide [20, 22, 29, 32]. Described
below are some of the most common non-hematologic ad-
verse reactions seen with lenalidomide treatment. Patients re-
ceiving Rd may also experience dexamethasone-related AEs,
such as hyperglycemia and psychological changes; if
suspected, the dexamethasone dose may be reduced [63].
Rash
Rash is a very common side effect of lenalidomide treatment
[21]. These skin reactions are generally mild-to-moderate in
severity; however, rash of higher grades may occur (Tables 3
and 4) [29, 30, 59]. Lenalidomide-induced rash may present
as patchy, raised, macular skin lesions, sometimes with local-
ized urticaria [59], and is more likely to occur during the first
cycle of therapy [64]. All patients should be routinely moni-
tored for skin-related AEs during treatment [65]. Mild-to-
moderate rash can be treated with antihistamines, topical cor-
ticosteroids, and/or appropriate dose modifications [59, 64,
65]. Treatment interruption or discontinuation should be con-
sidered for grade 2 or 3 skin rash, and lenalidomide must be
discontinued for angioedema, grade 4 rash, exfoliative or bul-
lous rash, or if serious reactions, including Stevens-Johnson
syndrome, toxic epidermal necrolysis, or Drug Reaction with
Eosinophilia and Systemic Symptoms, are suspected [21].
Patients should be informed of the signs of these serious reac-
tions and advised to seek medical attention immediately if
they develop any symptoms. Treatment should not be re-
sumed after discontinuation owing to any of these events [20].
Diarrhea and constipation
Diarrhea occurs frequently in patients treated with
lenalidomide (Tables 3 and 4), although most commonly at
lower grades [30], and may manifest as late as 17–24 months
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after treatment initiation [66]. If poorly managed, diarrhea can
lead to multiple physiologic abnormalities, reduce patients’
quality of life, and lead to unnecessary treatment discontinu-
ation [66, 67]; thus, proactive management is essential.
Symptomatic treatment of diarrhea with medications such as
loperamide or colesevelam, coupled with adequate hydration,
is appropriate for most patients [52, 68]; however, as research
suggests that lenalidomide-induced diarrhea may be related to
bile acid malabsorption (BAM), investigations for this condi-
tion should be carried out if practical, and a trial of bile acid
sequestrant therapy, along with dietary adjustments, initiated
[52, 67]. Bearing in mind that lenalidomide capsules contain
lactose, intolerance to lactose should also be considered [52].
Constipation is another common occurrence with
lenalidomide treatment (Tables 3 and 4) and, along with the
associated bowel discomfort, can be a disabling toxicity [68].
Lenalidomide-related constipation can be managed with gen-
eral supportive care measures, such as increased fluid and
fiber intake, pharmacological agents, increased physical activ-
ity, and laxatives or stimulants. Assessment for bowel obstruc-
tion, intravenous hydration, disimpaction, and referral to a
gastroenterologist may be required for severe cases [65, 68].
Dose interruptions/modifications may also be necessary [65].
Fatigue
Fatigue of grade 3 or higher has been reported in up to 18% of
lenalidomide-treated patients [69], and is a common reason for
treatment discontinuation [64]. While fatigue is common in all
patients with NDMM [65, 70], lenalidomide-treated patients
may experience more frequent and severe fatigue than patients
receiving placebo (Tables 3 and 4) [29] or bortezomib [71].
One initial approach to managing lenalidomide-associated
fatigue is to suggest that patients take the lenalidomide dose in
the evening. Other common causes of fatigue—such as ane-
mia, infection, hypothyroidism, and, in patients receiving Rd,
dexamethasone-related myopathy—should be considered, in-
vestigated, and treated if appropriate. If dexamethasone-
related myopathy is suspected, the dexamethasone dose may
be reduced. If fatigue is severe, lenalidomide dose reduction
may be considered. Depression, anxiety, disturbed sleep, and
reduced exercise capacity are also known to contribute to fa-
tigue in patients with NDMM [70], and effective management
of any such contributing factors can reduce symptoms.
General supportive care includes individualized, moderate
prescriptive exercise; pain relief (although thismay exacerbate
fatigue); treatment for depression; and measures to improve
sleep [65, 70, 72].
Infections
Although susceptibility to infections is increased in all patients
with MM, elevated infection rates have been reported with Rd
versus MPT in ASCT-ineligible NDMM patients, and with
lenalidomide maintenance versus placebo post-ASCT
(Tables 3 and 4) [21, 24, 29, 30, 73]. Meta-analyses indicate that
the overall incidence of grade 3/4 or high-grade infection in
lenalidomide-treated patients is around 14% [69, 74], including
a number of fatal events in clinical trials [74]. The risk of infec-
tion appears to be greater during induction than during mainte-
nance treatment [73]. Although the precise immunomodulatory
effects of lenalidomide are still being elucidated, studies suggest
that the drug has both immunostimulatory and immunosuppres-
sive effects [34, 75]; it is likely that the latter, as well as the
hematologic toxicity, play a role in the increased susceptibility
to infection observed in lenalidomide-treated patients.
Preventive and therapeutic management of infection is es-
sential for all patients with MM who receive lenalidomide
treatment [73]. When lenalidomide is administered in combi-
nation with dexamethasone, routine antibiotic prophylaxis
should be considered for the first 3 months of therapy—
particularly in patients with aggressive disease, a history of
infectious complications, or neutropenia [64]. Additionally, pa-
tients experiencing chronic non-neutropenic infections may re-
quire dexamethasone dose reductions. All patients receiving
lenalidomide should be advised to seek medical attention
promptly at the first sign of infection (e.g., cough, fever) [21].
In particular, patients with known risk factors for infection re-
quire close monitoring. As fatal outcomes have been reported
following hepatitis B virus (HBV) reactivation, HBV status
should be established before starting lenalidomide treatment,
and patients with prior HBV infection must be closely moni-
tored during therapy for signs of active HBV. Clinical data
suggest that routine acyclovir prophylaxis in lenalidomide-
treated patients can prevent varicella zoster/complicated herpes
simplex virus infection, and should be considered in all patients
receiving lenalidomide [76].
Vaccination may also be advisable to reduce the risk of
infection. Studies of lenalidomide maintenance post-ASCT
have reported responses to a number of common vaccines,
including inactivated pertussis, diphtheria, tetanus,
Haemophilus influenzae, and pneumococcal [77], as well as
the live attenuated measles-mumps-rubella and herpes zoster
[78], in up to 76% of patients, with no apparent vaccine-
related side effects.
Second primary malignancies
A number of studies and a comprehensive meta-analysis have
shown that the risk of SPM development is increased in pa-
tients receiving lenalidomide versus control groups (Tables 3
and 4) [23, 29, 30, 79]. In a meta-analysis of seven clinical
studies, including both first-line and maintenance treatments,
the cumulative incidence of all SPMs at 5 years was 6.9% in
NDMM patients who received lenalidomide versus 4.8% in
those who did not (HR 1.55 [95% CI, 1.03–2.34]; p = 0.037)
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[79]. The observed difference appeared attributable primarily
to an increased incidence of hematologic SPMs, the cumula-
tive 5-year incidence of which was 3.1% in lenalidomide-
treated patients versus 1.4% in controls (HR 3.8 [95% CI,
1.15–12.62]; p = 0.029), with no significant differences being
observed in the rates of solid SPMs. Further, the authors con-
cluded that the increased risk of hematologic SPMs was driv-
en largely by treatment strategies incorporating both
lenalidomide and melphalan [79]. In the FIRST trial, the inci-
dence of SPMswas slightly reduced in the Rd versus theMPT
arm (7% versus 9%) [24], and it should be noted that adding
bortezomib to the Rd doublet does not appear to increase the
SPM risk [16].
Studies suggest that lenalidomide maintenance therapy is
associated with a marked increase in SPM risk; however, it
should be noted that all patients who received post-ASCT
lenalidomide maintenance in these studies had previously re-
ceived high-dose melphalan, a known risk factor for SPMs
[80]. Nevertheless, in the meta-analysis of data from three
maintenance studies, rates of hematologic and solid-tumor
SPMs were 6.1% and 7.3% among lenalidomide recipients
versus 2.8% and 4.2% among patients assigned to placebo
or observation [33]. Similar figures were reported for overall
SPM incidence in patients receiving post-transplant mainte-
nance with lenalidomide versus active observation in the
Myeloma XI study (5.8% versus 2.0%; adjusted HR 1.65
[95% CI, 0.46–6.00]; p = 0.444) [81].
Despite the elevated risk of SPMs, the risk of death from
MM significantly outweighs the risk of death from SPMs in
patients treated with melphalan and either concurrent or se-
quential lenalidomide [82], and in those treated with
lenalidomide maintenance [30, 33]. Nevertheless, clinicians
should discuss the potential increased risk of SPMs with pa-
tients, to enable them to reach an informed decision. The
IMWG consensus on SPMs recommends bone marrow exam-
ination with cytogenetic analysis for all patients initiating
lenalidomide maintenance, and advocates “a low threshold
for careful bonemarrow analysis with karyotyping for patients
with unexplained cytopenias that persist despite lenalidomide
withdrawal” [82]. Further, consideration should be given to
combining lenalidomide with agents other than melphalan
[79], particularly in the light of data suggesting that, in patients
ineligible for ASCT, Rd until progression is associated with a
significant survival advantage relative to other first-line treat-
ments incorporating melphalan (bortezomib, melphalan, and
prednisone [VMP]; MPT; and MP) [83].
Impact of long-term lenalidomide therapy
on subsequent treatment
While the administration of lenalidomide as either first-line
treatment or post-ASCT maintenance therapy can result in
prolonged disease control, the majority of patients eventually
relapse and require second-line therapy. At this point, prior
lenalidomide treatment becomes a factor when selecting from
the currently available therapeutic options. Several clinical
issues are relevant, such as whether patients with biochemical
relapse following long-term treatment with first-line Rd are
truly refractory to lenalidomide, or could benefit from a
lenalidomide-based second-line regimen. Further research is
needed to answer this important question. In the maintenance
setting, patients with biochemical relapse may benefit from
treatment re-intensification (increasing lenalidomide to “full
dose”/adding dexamethasone/adding a third compound), to
prevent further and symptomatic disease progression.
A full, symptomatic relapse probably indicates that pa-
tients are refractory to lenalidomide, and second-line treat-
ment will need to include agents with alternative modes of
action, such as proteasome inhibitors, conventional chemo-
therapy, and/or monoclonal antibodies. Many of the new or
emerging standards of care for second-line treatment are
Rd-based combinations (e.g., carfilzomib-Rd [KRd],
ixazomib-Rd [IRd], elotuzumab-Rd, daratumumab-Rd), al-
though clinical trial data regarding their efficacy and safety
in patients previously treated with lenalidomide are cur-
rently lacking; however, a retrospective analysis suggests
that KRd may be effective in this setting [84]. Treatment
re-intensification by combining lenalidomide with conven-
tional cytotoxic agents is another second-line option that
has shown promise [85–87]. In the phase 1/2 REPEAT
trial, in which patients with lenalidomide-refractory MM
received lenalidomide, low-dose cyclophosphamide, and
prednisone until disease progression, 67% of patients
achieved a partial response or better, including 23%
VGPR and 5% CR [85]. Median PFS and OS after
24.5 months of follow-up were 12.1 and 29.0 months, re-
spectively. Notably, response and survival were similar in
patients with high- versus standard-risk cytogenetics, and
the hematologic toxicity of this regimen was similar to that
seen with Rd.
In the absence of strong clinical trial evidence, deci-
sions regarding second-line therapy in patients who have
become refractory to lenalidomide must be made on a
case-by-case basis, taking into account factors such as
the duration of first-line lenalidomide treatment, prior re-
sponsiveness to lenalidomide, previous and current toxic-
ities, and the patient’s condition and risk status [88]. A
number of alternatives to Rd-based combinations—such
as pomalidomide, bortezomib, and dexamethasone (PVd)
[89] and elotuzumab, pomalidomide, and dexamethasone
(EPd) [90]—are now available, with more under investi-
gation. Long-term toxicities may also influence subse-
quent treatment selection. Patients with renal complica-
tions should avoid nephrotoxic drugs where possible
[72] and, although neuropathy is uncommon with
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lenalidomide, neurotoxic agents should be avoided in pa-
tients with long-lasting neurological symptoms. In
transplant-ineligible patients relapsing more than 6 months
after discontinuing lenalidomide, repeating first-line Rd
treatment is appropriate [15].
Conclusions
A substant ia l body of research has establ ished
lenalidomide as a key therapeutic option for patients with
NDMM, both as a component of first-line regimens for
patients ineligible for ASCT and as maintenance therapy
post-ASCT. A number of studies in which newer therapies
(e.g., ixazomib, elotuzumab) have been added to the Rd
backbone are currently underway in ASCT-ineligible pa-
tients; their results are eagerly anticipated. The finding
that adding daratumumab to Rd deepens response and
significantly prolongs survival versus Rd alone highlights
the significant benefits that can be achieved by combining
Rd with novel agents [25]. In the maintenance setting,
combinations of other agents with lenalidomide are being
investigated, and the outcomes of these lines of research
are likely to further expand the clinical utility of
lenalidomide. Consequently, it is anticipated that
lenalidomide will continue to play an important role in
the treatment of NDMM for some time to come, and phy-
sicians should be aware of optimal management ap-
proaches to achieve the best outcomes for their patients
when using this drug.
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